End Drug Shortages Alliance
End Drug Shortages Alliance is a nonprofit, member-driven coalition of 100+ healthcare organizations that coordinates hospitals, GPOs, distributors, and manufacturers to prevent drug shortages through transparency, data sharing, and rapid response initiatives.
- Company typePrivate
- Founded2021
- HeadquartersWilmington, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What End Drug Shortages Alliance does
End Drug Shortages Alliance (EDSA) is a member-driven, industry-led nonprofit alliance founded in 2021 and headquartered in Wilmington, Delaware, that coordinates healthcare and pharmaceutical supply-chain stakeholders to mitigate drug shortages. The organization comprises more than 100 member organizations spanning hospitals and health systems (Mayo Clinic, Ascension, Prisma Health, Ochsner Health, Intermountain Health), group purchasing organizations (Vizient, Premier), pharmaceutical distributors (McKesson, Cencora, Morris & Dickson), manufacturers (Pfizer, Hikma, Civica Rx, STAQ Pharma), patient advocates (Angels for Change), and quality and policy organizations (ASHP, US Pharmacopeia, Duke-Margolis Institute for Health Policy). EDSA operates a Rapid Response Team to manage global drug-supply disruptions and runs four committees covering Supply Readiness, Transparency & Redundancy, Quality, and Pediatric & Special Populations.
EDSA's flagship product is the Drug Resiliency & Transparency Pilot, a six-month initiative launched in August 2024 through the Biden Cancer Moonshot program that brought together seven children's hospitals, three national distributors, and three advising partners (Children's Hospital Association, US Pharmacopeia, Angels for Change) to share inventory data on seven critical pediatric cancer drugs. The pilot demonstrated feasibility of proactive, well-governed supply-chain transparency, with 100% of respondents indicating willingness to participate in future data-sharing initiatives. The alliance also maintains a member resource portal (Atlas), publishes an annual report, and offers webinars, publications, and member-only resources as part of its core deliverables. Underlying technology is a data-sharing platform enabling pre-shortage visibility into supply conditions.
EDSA generates revenue through tiered annual membership dues based on each member organization's annual gross revenue and tax status, with dues self-disclosed on the membership application and payment required before member benefits are unlocked. The go-to-market motion is sales-led, targeting enterprise healthcare organizations through a structured membership application process. The alliance operates with 1-10 employees and provides multi-tiered, organization-based access that allows all colleagues within a member organization to participate under a single membership. Geographic scope is the United States.
End Drug Shortages Alliance firmographics
Firmographics- Name
- End Drug Shortages Alliance
- Legal name
- End Drug Shortages Alliance
- Website
- https://enddrugshortages.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- End Drug Shortages Alliance is a nonprofit, member-driven coalition of 100+ healthcare organizations that coordinates hospitals, GPOs, distributors, and manufacturers to prevent drug shortages through transparency, data sharing, and rapid response initiatives.
- Ownership category
- akta.pro rank
End Drug Shortages Alliance industry classification
Industry- Product category
- Healthcare Industry Coalition / Pharmaceutical Supply Chain Collaboration
- NAICS
- Voluntary Health Organizations (813212)
- SIC
- Services-Membership Organizations (8600)
- akta.pro primary industry
- Hospital Shared Services, GPOs & System Support Organizations (HLAFAAAO)
- akta.pro secondary industries
- Health, Pharmaceuticals & Medical Devices Regulatory Cooperation (BPADANAJ), Medication Inventory, Procurement & Supply Chain (Pharmacy) (HLACAKAI)
Keywords
Where End Drug Shortages Alliance is headquartered
LocationHeadquarters
- HQ city
- Wilmington
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
End Drug Shortages Alliance business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Revenue model
- Membership Dues: Organization-based membership with annual membership fees. Tier is based on organization's annual gross revenue and tax status. All colleagues can participate under their organization's membership.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Tiered membership based on organizational annual gross revenue and tax status |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
End Drug Shortages Alliance product offering
Product offeringCore offering
End Drug Shortages Alliance (EDSA) is a member-driven, industry-led nonprofit alliance that coordinates healthcare and supply chain stakeholders to prevent and mitigate drug shortages. The alliance recruits hospitals, GPOs, manufacturers, patient advocates, and supply chain leaders through tiered annual membership, granting members access to exclusive committees, events, publications, webinars, advocacy efforts, and collaborative initiatives such as the Drug Resiliency & Transparency Pilot. Core value is delivered through shared supply chain visibility, Rapid Response Team activation during global disruptions, and coordinated industry-wide action on essential medicine supply continuity.
Product overview
The End Drug Shortages Alliance is a member-driven and industry-led alliance of healthcare and supply chain leaders focused on strengthening essential medicine supply and safeguarding patient access. The organization does not offer a traditional technology product but rather operates collaborative programs including the Drug Resiliency & Transparency Pilot, which tests responsible transparency mechanisms for supply resiliency before shortages occur. The alliance provides member-exclusive resources including committees, webinars, publications, and access to collaborative initiatives aimed at preventing future drug shortages through transparency, reliability, and resiliency efforts.
Differentiator
Problem solved
Functional benefit
Products and services
- Drug Resiliency & Transparency Pilot
- EDSA Organizational Membership
Quantifiable outcome
- 100% of pilot respondents stated they would participate in future data-sharing initiatives
- +1 more outcomes
Companies that use End Drug Shortages Alliance
Customer profileNamed customers6 records
Segments6 records
Ideal customer profiles4 records
End Drug Shortages Alliance technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
End Drug Shortages Alliance partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered core and flagship.
- Children's Hospital AssociationcoreThe Children's Hospital Association is an advising partner in the Drug Resiliency & Transparency Pilot, working with EDSA and seven children's hospitals to share inventory data for pediatric cancer drugs. The alliance focuses on transparency, reliability, and resiliency in drug supply chains.
- US PharmacopeiacoreUS Pharmacopeia serves as an advising partner in the Drug Resiliency & Transparency Pilot. Vimala Raghavendran, VP of Informatics, Product Development, serves on the EDSA Advisory Board.
- PfizercorePfizer participates in EDSA with Meera Bhavsar serving as Vice President, US Hospital Sterile Injectables Lead on the Advisory Board. Pfizer contributes to discussions on supply continuity and long-term policy solutions.
- McKessoncoreMcKesson, a major pharmaceutical distributor, participates in EDSA with Scott Miller serving as President, Health Systems on the Advisory Board. McKesson is also a pilot participant in the Drug Resiliency & Transparency Pilot.
- CencoracoreCencora (formerly AmerisourceBergen) participates in EDSA with Lauren DeReus serving as Sr. Vice President, Partnership & Sales on the Advisory Board. Cencora is also a pilot participant in the Drug Resiliency & Transparency Pilot.
- VizientcoreVizient participates in EDSA with Mittal Sutaria serving as Sr. Vice President, Contract & Program Services on the Advisory Board. Vizient provides research on drug shortage costs to the alliance.
- Premier Inc.corePremier Inc. participates in EDSA with Justin Schneider serving as Vice President of Pharmacy on the Advisory Board.
- Civica RxcoreCivica Rx participates in EDSA with Allan Coukell serving as Chief Government Affairs and Public Policy Officer on the Advisory Board.
- ASHPcoreASHP (American Society of Health-System Pharmacists) participates in EDSA with Michael Ganio serving as Sr. Director, Pharmacy Practice and Quality on the Advisory Board.
- Duke-Margolis Institute for Health PolicycoreDuke-Margolis Institute for Health Policy participates in EDSA with Stephen Colvill serving as ReVAMP Consortium Lead on the Advisory Board.
- Morris & DicksoncoreMorris & Dickson is a pharmaceutical distributor and pilot participant in the Drug Resiliency & Transparency Pilot, sharing inventory data for pediatric cancer drugs.
- Angels for ChangecoreAngels for Change is a patient advocacy organization and advising partner in the Drug Resiliency & Transparency Pilot. Laura Bray, Chief Change Maker, serves on the EDSA Advisory Board.
- HikmacoreHikma participates in EDSA with Neal Gervais serving as Sr. Director, National Accounts on the Advisory Board.
- STAQ PharmacoreSTAQ Pharma participates in EDSA with Mark Spiecker serving as Vice President of Pharmacy on the Advisory Board.
- Biden Cancer MoonshotflagshipThe Drug Resiliency & Transparency Pilot was launched through the Biden Cancer Moonshot initiative, bringing together seven hospitals, distributors, and advising partners to address pediatric cancer drug shortages through data sharing.
Scale indicators4 records
Recent moves5 records
Expansion highlights5 records
End Drug Shortages Alliance competitors and assessment
Company assessmentDirect peers
- BioPhorum: Industry consortium that convenes biopharmaceutical manufacturers and suppliers to collaborate on shared supply chain, quality, and production challenges. Highly analogous member-driven, pre-competitive collaboration model targeting pharma supply chain resilience.
- Angels for Change: Nonprofit patient-advocacy organization dedicated to ending drug shortages, particularly in oncology and pediatrics. Directly comparable mission, member/partner of EDSA, and operates a parallel advocacy and supply-chain transparency agenda.
- Civica Rx: Nonprofit pharmaceutical company whose mission is to reduce and prevent drug shortages by manufacturing essential medicines. Highly comparable to EDSA: nonprofit structure, healthcare-coalition model, and shared focus on U.S. essential-medicine supply reliability.
- American Society of Health-System Pharmacists (ASHP): National membership organization for hospital and health-system pharmacists with deep engagement on drug shortages, supply-chain standards, and pharmacy practice quality. Overlapping nonprofit, member-driven advocacy model and direct overlap with EDSA's quality and supply-readiness committees.
- Phlow Corporation: Public-benefit pharmaceutical manufacturer focused on essential medicines and U.S. supply chain resilience for critical drugs. Directly comparable mission to mitigate shortages, with overlapping federal-government alignment (BARDA-funded).
- Children's Hospital Association: National association of children's hospitals that convenes pediatric providers for advocacy, supply-chain collaboration, and shared initiatives. Member and pilot partner of EDSA, with a directly comparable alliance-of-providers model.
- Healthcare Distribution Alliance (HDA): National trade association representing pharmaceutical distributors including McKesson and Cencora. Closely comparable membership-alliance model serving the U.S. drug supply chain, with overlapping member rosters and policy advocacy mission.
Broad incumbents
- McKesson: One of the largest U.S. pharmaceutical distributors and a foundational EDSA member and pilot participant. Comparable through its central role in drug distribution and shortage-management operations that EDSA is seeking to coordinate.
- Vizient: Largest U.S. healthcare performance improvement company and GPO, providing pharmacy contracting, analytics, and supply-chain services. EDSA member/advisory partner with significant overlap in pharmaceutical contracting and shortage analytics.
- Premier Inc. Major U.S. healthcare GPO and performance improvement company serving hospitals and health systems with pharmacy services and supply-chain solutions. EDSA advisory-board partner with comparable stakeholder mix and drug-shortage initiatives.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
End Drug Shortages Alliance social profiles
Digital presenceEnd Drug Shortages Alliance financial estimates
Financial estimateRevenue estimate
Valuation estimate
End Drug Shortages Alliance leadership team
Management profileNumber of profiles
Profiles18 records
End Drug Shortages Alliance funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
End Drug Shortages Alliance M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about End Drug Shortages Alliance
What does End Drug Shortages Alliance do?
End Drug Shortages Alliance (EDSA) is a member-driven, industry-led nonprofit alliance that coordinates healthcare and supply chain stakeholders to prevent and mitigate drug shortages. The alliance recruits hospitals, GPOs, manufacturers, patient advocates, and supply chain leaders through tiered annual membership, granting members access to exclusive committees, events, publications, webinars, advocacy efforts, and collaborative initiatives such as the Drug Resiliency & Transparency Pilot. Core value is delivered through shared supply chain visibility, Rapid Response Team activation during global disruptions, and coordinated industry-wide action on essential medicine supply continuity.
Is End Drug Shortages Alliance a public or private company?
End Drug Shortages Alliance is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was End Drug Shortages Alliance founded?
End Drug Shortages Alliance was founded in 2021. It employs 1 to 10 people.
Where is End Drug Shortages Alliance based?
End Drug Shortages Alliance is headquartered in Wilmington, United States, in the North America region.
How does End Drug Shortages Alliance make money?
One revenue line is on record: membership Dues.
Who are End Drug Shortages Alliance's main competitors?
Direct peers on record are BioPhorum, Angels for Change, Civica Rx, American Society of Health-System Pharmacists (ASHP), Phlow Corporation, Children's Hospital Association and Healthcare Distribution Alliance (HDA). Broad incumbents are McKesson, Vizient and Premier Inc..
Does End Drug Shortages Alliance have an API?
No public API is recorded for End Drug Shortages Alliance.
What industry is End Drug Shortages Alliance in?
End Drug Shortages Alliance's product category is Healthcare Industry Coalition / Pharmaceutical Supply Chain Collaboration. Its primary akta.pro industry code is HLAFAAAO, Hospital Shared Services, GPOs & System Support Organizations, with a secondary code of BPADANAJ, Health, Pharmaceuticals & Medical Devices Regulatory Cooperation. Its NAICS code is 813212 and its SIC code is 8600.